Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
about
Dalbavancin for the treatment of acute bacterial skin and skin structure infectionsSafety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesDalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery.Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report.Infective endocarditis.Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions.Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.A young patient with fever after heart transplantation
P2860
Q26799598-77A22ACC-FEB8-4B85-9977-88689EF841C5Q28069555-1F0C26AB-ED2F-4602-8E3B-33210DD40C34Q36073405-DF2F7763-A3AE-444C-8AD9-8F4C46215984Q36319908-B188AC81-D8FD-4A91-9049-CE3543616242Q38646905-5D3BC755-A0B5-4A87-9002-091BF0A0CE22Q38907793-EB4ED675-6276-4ACF-A5FA-74FF40BE0865Q39164161-3716226F-CF4D-405B-B5F8-A88989680A47Q40930124-B3EECC78-DC7E-4763-A999-3306DFF291D2Q45059895-340FDB0D-F12E-4D7B-B247-921E3A2F9E52Q47140222-F120B17B-027C-4763-A4F2-C31D07892EA5Q48247125-E879E661-B9EA-40AD-BCD6-B094CE56EF70Q48301411-7F1AC1B4-10D4-4305-82CA-8A72B4ECD94AQ52943386-C0AFC767-2F8F-4A2C-A9BD-409343653505Q53708430-AE6AC7AE-615E-4650-AF79-A0564B3D1E58Q55512133-1B671B26-1D3C-41C7-8219-4D95A6A40880Q59137232-983D5268-9B93-4F25-AAAD-7D14801C1A1A
P2860
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
@ast
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
@en
type
label
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
@ast
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
@en
prefLabel
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
@ast
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
@en
P2093
P2860
P356
P1476
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
@en
P2093
Chris Rubino
Craig R Sprenger
James Baldassarre
Michael W Dunne
Sailaja Puttagunta
Scott Van Wart
P2860
P304
P356
10.1128/AAC.04550-14
P407
P577
2015-01-05T00:00:00Z